AzTrials
AzTrials

Pregnant WomenNCT07258329

Screening for Intrapartum Fetal Compromise Using Placental Biomarkers

An observational study of Pregnant Women, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 2 sites in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to investigate the association between placental markers (sFlt-1, PlGF, and the sFlt-1/PlGF ratio) and intrapartum fetal compromise, assessed on the basis of the cardiotocographic tracing. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Pregnant Women
How many people
428 participants
Where
2 sitesItaly
Study dates
28 Mar 2025to 1 Oct 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: The study will enroll pregnant patients who present to the Obstetrics Units of the participating centers

Who may be able to join

  • Age ≥ 18 years
  • Gestational age ≥ 32 weeks
  • Obtaining informed consent for participation in the study and for the processing of personal data
  • Pregnant patients with an indication to perform placental marker testing as part of routine clinical practice
  • Patients who will deliver at the Obstetrics Units of the participating centers

Who cannot join

  • Absolute contraindications to vaginal delivery (placenta previa, vasa previa, placenta accreta, previous myomectomy)

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Antonio Farina, MD contact

0512144377

antonio.farina@unibo.it

Italy2 sites, 2 recruiting
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    Bologna, Bologna, 40138

    Antonio Farina, MD, 0512144377, antonio.farina@unibo.it

    Recruiting
  • IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Milano, 20122

    Irene Cetin, MD, 0255032240, irene.cetin@unimi.it

    Not yet recruiting

Other trials in Italy

About this study

Official title: Screening Della Compromissione Fetale Intrapartum Mediante Utilizzo Dei Marcatori Placentari

This study aims to investigate the association between placental markers (sFlt-1, PlGF, and the sFlt-1/PlGF ratio) and intrapartum fetal compromise, assessed on the basis of the cardiotocographic tracing.

Read the detailed description

The development of placentation during pregnancy involves two simultaneous processes: the invasion of maternal spiral arteries by cytotrophoblasts and the branching of the fetal vascular tree. These mechanisms, regulated by factors such as VEGF, PlGF, sFlt-1, and PAPP-A, ensure an adequate supply of oxygen and nutrients to the fetus. When these processes are impaired, placental dysfunction develops, characterized by high vascular resistance, hypoperfusion, and oxidative stress, which can predispose to complications such as preeclampsia, fetal growth restriction, gestational diabetes, placental abruption, and preterm birth.

During labor, uterine contractions can reduce uteroplacental perfusion by up to 60%. A healthy fetus with a normally functioning placenta can tolerate these transient reductions through compensatory mechanisms, whereas a fetus with abnormal placentation may exhibit signs of compromise, such as abnormal heart rate patterns or the presence of meconium, and, in cases of severe hypoxia, may face more serious risks.

The clinical challenge is to identify, before labor, fetuses that, despite appropriate growth, have a placenta unable to withstand the stress of delivery. Some studies have investigated Doppler velocimetry, particularly the Cerebro-Placental Ratio, but its predictive ability at term is modest. The role of placental markers (PlGF, sFlt-1, sFlt-1/PlGF) in predicting intrapartum fetal compromise also remains uncertain, with conflicting results reported in the literature. Since these markers are altered in pregnancies with placental dysfunction, their combination with antenatal risk factors may allow better identification of fetuses at risk, guiding clinicians in labor management and the choice of delivery mode.

This study will enroll participants using a retrospective and prospective approach. The primary aim is to evaluate the association between placental markers and intrapartum fetal compromise based on cardiotocographic tracings. Secondary aims include assessing their relationship with fetal acidosis, low Apgar scores, and admission to the neonatal intensive care unit.

Conditions
Pregnant Women

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants Diagnosed with Intrapartum Fetal Compromise Based on Cardiotocographic Tracing

    Association between placental markers and intrapartum fetal compromise

    Measured: At the time of delivery

Secondary outcomes (3)
  1. Number of Participants With Fetal Acidosis (pH ≤ 7.0 or Base Excess ≥ -12)

    Association between placental markers and fetal acidosis

    Measured: At the time of delivery

  2. Number of Participants With 5-Minute Apgar Score < 7

    Association between placental markers and low birth Apgar score

    Measured: At the time of delivery

  3. Number of Newborns Transferred to Neonatal Intensive Care Unit (NICU) for Birth-Related Hypoxia

    Association between placental markers and admission to the neonatal intensive care unit

    Measured: At the time of delivery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Dec 2025
  2. Study start28 Mar 2025
  3. Primary completion1 Feb 2028 (estimated)
  4. Study completion1 Oct 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Other
Enrolment
428 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07258329
Sponsor's protocol ID
PLGF_IFC
Status last verified
Nov 2025
First submitted
19 Nov 2025
Last updated
2 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Pregnant Women, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 2 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Antonio Farina, MD (0512144377, antonio.farina@unibo.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants Diagnosed with Intrapartum Fetal Compromise Based on Cardiotocographic Tracing (time frame: At the time of delivery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in